[HTML][HTML] Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
G Etienne, S Dulucq, FE Nicolini, S Morisset… - …, 2014 - ncbi.nlm.nih.gov
Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete
molecular response allowing discontinuation without relapse. We set out to evaluate the …
molecular response allowing discontinuation without relapse. We set out to evaluate the …
[HTML][HTML] Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV
C Michel, A Burchert, A Hochhaus, S Saussele… - …, 2019 - ncbi.nlm.nih.gov
Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib. In the
randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition …
randomized German Chronic Myeloid Leukemia-Study IV, more potent BCR-ABL inhibition …
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia …
N Takahashi, T Tauchi, K Kitamura, K Miyamura… - International journal of …, 2018 - Springer
The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …
[HTML][HTML] Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian …
N Thielen, B van der Holt, JJ Cornelissen… - European journal of …, 2013 - Elsevier
Background Tyrosine kinase inhibitors treatment in responding chronic myeloid leukaemia
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …
(CML) patients is generally continued indefinitely. In this randomised phase II trial, we …
Cytogenetic and molecular responses in chronic phase chronic myeloid leukaemia patients receiving low dose of imatinib for intolerance to standard dose
M Breccia, L Cannella, C Stefanizzi… - Hematological …, 2010 - Wiley Online Library
Imatinib mesylate is the gold standard treatment of chronic myeloid leukaemia (CML) and
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …
400 mg/day is considered the standard dose. Although it is generally well tolerated, some …
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien… - … England Journal of …, 2006 - Mass Medical Soc
Background The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to …
[HTML][HTML] Discontinuation of imatinib therapy after achieving a molecular response in chronic myeloid leukemia patients.
FX Mahon, D Rea, F Guilhot, F Huguet, FE Nicolini… - Blood, 2009 - Elsevier
Abstract Abstract 859 Background Imatinib (IM) has greatly improved survival rates in
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …
chronic myeloid leukemia*(* CML). However, all patients (pts) must continue treatment for an …
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era
M Breccia, G Alimena - Critical reviews in oncology/hematology, 2011 - Elsevier
Tyrosine kinase inhibitors (TKI) have dramatically changed the management and the
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …
outcome of chronic myeloid leukemia (CML) patients. Imatinib is recognized as gold …
[HTML][HTML] Molecular response after 3 months of 1st line imatinib therapy is predictive for treatment failure and disease progression in patients with chronic phase chronic …
B Hanfstein, MC Müller, P Erben, S Schnittger… - Blood, 2010 - Elsevier
Abstract Abstract 360 Introduction: The lack of a sufficient response to first line imatinib
treatment has been observed in a substantial proportion of CML patients and has been …
treatment has been observed in a substantial proportion of CML patients and has been …
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular …
HY Yhim, NR Lee, EK Song, CY Yim, SY Jeon, S Shin… - Leukemia research, 2012 - Elsevier
The aims were to investigate the feasibility of imatinib mesylate (IM) discontinuation in
chronic myeloid leukemia patients who were initially treated with IM and achieved complete …
chronic myeloid leukemia patients who were initially treated with IM and achieved complete …